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1INTRODUCTION
Alcohol consumed by all strata of society remains to be a major cause for
morbidity and mortality worldwide. Unquestionably ethanol is a hepatotoxic
compound that leads to serious form of alcoholic liver disease1.
Chronic alcoholism results in changes of the intestinal epithelial barrier,
increase pro-inflammatory cytokine production, generation of ROS which are the key
factors in mediating alcoholic liver disease2.
Zinc deficiency has been documented with alcoholic liver disease
moreover the decrease in serum zinc correlates with the progression of liver disease3.
It is also a well-known fact that zinc is a co-factor for enzyme alkaline
phosphatase. This study aims at assessing the zinc status and alkaline phosphatase in
patients with alcoholic liver disease.
2AIMS AND OBJECTIVES
The aim is to evaluate zinc and alkaline phosphatase activity in patients
with alcoholic liver disease.
The objectives are
 To determine serum zinc.
 To estimate alkaline phosphatase activity.
 To assess the correlation between zinc and alkaline phosphatase activity.
 To analyze the state of zinc in various stages of alcoholic liver disease.
 To estimate the need for evaluating zinc status and supplementing zinc in
patients with alcoholic liver disease.
3ALCOHOLIC LIVER DISEASE-EPIDEMIOLOGY
Alcohol attributable injuries and negative impacts are now becoming the
major concern to the health of the public.
Consuming alcoholic beverages is the potent etiological factor for the
development of alcoholic liver diseases(ALD), ranging from fatty liver to
hepatocellular carcinoma with varying rates of development in both genders
depending on the quality , quantity  and duration of the drink.
According to Global Information System on Alcohol and Health (
GISAH) data,3.3 million people die annually4.
In 2010, total intake worldwide was 6.2 litres of pure alcohol per person
of 15 years and above4
According to WHO ,total consumption by male drinkers 23.9 litres ,
female drinkers 10.4 litres of pure alcohol in India5.Cirrhosis per 1 lakh population is
22.1%in male and 52.4% in female.
Global distribution of Daily Adjusted Life Years (DALY) by disease or
injury is 9.6%6.
The goal of WHO by year 2020 is to reduce mortality rate below 3.2 per
1 lakh population6.
4Cirrhosis Morbidity and Mortality and Average Alcohol Consumption
The strong link between heavy or excessive alcohol use and the development of
liver disease took on added significance in the middle of the 20th century, when
several researchers began exploring cirrhosis as a potential marker for levels of
alcohol problems in populations Of particular importance was the discovery of a
relationship between cirrhosis mortality rates and per capita levels of alcohol
consumption in the population.
5This relationship has proved to be remarkably strong and has been consistently
observed across time periods and in various regions of the world European researchers
have observed a lagged relationship between cirrhosis mortality and consumption
measures, with the rate of cirrhosis mortality in a year being influenced by the alcohol
consumption rates of several previous years
To account for this effect, Skog (1980) developed a “distributed lag model,” in
which the effects of alcohol consumption in a year are distributed over the next several
years. Using this model, he was able to explain an apparent inverse relationship
between consumption and cirrhosis mortality rates in Great Britain between 1931 and
1958 (Popham 1970). Incorporating the distributed lag model into the data produced
the expected positive relationship between consumption and cirrhosis mortality.
6ANATOMY OF LIVER
The human liver constitutes 2% of adult body weight, it is around 1400
gms in females and 1800 gms in male.
Externally the liver is divided by falciform ligament into right and left
lobes and attached to the anterior abdominal wall  , through this ligament. It is a
remnant of ligamentum teres ,which is vestigeal and recanalises during portal
hypertension (PHT)7.
Couinaud’s Segmental Classification :
This is proposed for surgical resection purpose .Here liver is divided into
anterior and posterior segment by the right hepatic vein .
Segment 1 –posterior caudate lobe.
Segment 2 ,3 –left lateral
Segment 4-left medial
Segment 5,8 – right anterior
Segment 6,7 – right posterior.7
7Diagram of liver
Segmental Anatomy
Arterial blood supply is mainly by  portal vein (80%) and balance by
hepatic artery(20%). Venous outflow is by 3 hepatic veins which directly drain into
inferior vena cava. Lymphatics-The space of Disse and clefts of Mall produce lymph
fluid. Liver has both parasympathetic and sympathetic nerve supply.7
8Microscopy  of  hepatic system
Microarchitecture of liver:
The liver lobule consists of central vein, array of hexagonal hepatocytes,
sinusoids and canaliculi carrying blood and bile. The periphery consist of the portal
triad (hepatic artery, portal vein and bile duct).8
9PHYSIOLOGY OF LIVER
Liver performs various functions like synthetic, storage, secretory,
vascular, detoxification and metabolic function.
 Storage of glycogen, 90% retinol, Vit D, B12 and iron.
 Synthesis of ketone bodies, urea ,bile, plasma proteins, coagulation factors.
 Catabolism of heme , steroid and various drugs.
 Detoxification and modification of xenobiotic .
 Metabolism of carbohydrates, lipid and proteins8.
 Phagocytic activity of liver is performed by kupffer cells present in the
sinusoids7.
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ALCOHOL  METABOLISM
A drink containing ethyl alcohol , when consumed becomes an alcoholic
beverage. According to WHO the alcohol content necessary for the beverage, is the
percentage pure alcohol by volume and it varies in different parts of the world like
0.7% in south east asia,1.1%in America,1.4 %in Europe6.
It has a nutrient value of 7.1 Kcal/kg. Alcoholism is defined as repeated ingestion of
alcohol with resultant dependency.
Alcohol is an agent which on chronic ingestion causes various conditions like
Hypoglycemia,
Wernickes-korsakoffspsychosis,
Ketoacidosis,
Gastritis,
Pncreatitis,
Cirrhosis liver,
Neuropathies,
Dementia,
11
Cardiomyopathy
Carcinoma of mouth ,larynx and oesophagus9.
Absorption and Elimination
Gastro intestinal absorption of alcohol is by simple diffusion, 80% in
duodenum and upper jejunum.
Elimination is by liver metabolism, certain amount by renal < 1 % and lungs
1.5 %.Lipid insoluble nature of alcohol leads to attain higher levels in obese body9.
Metabolism:
Enzyme involved in alcohol metabolism are:
 Alcohol dehydrogenase – major enzyme
 Isoenzyme of Cytochrome P-450, Microsomal ethanol oxidizing system
– (MEOS)
 Catalase
 Xanthine oxidase
12
ADH
Alcohol Dehydrogenase (ADH) system:
5 classes of ADH isoenzymes are present in humans which is encoded
by different gene loci. Expression of genes of ADH are very specific.
Class I ADH activity is more in the liver with high affinity Vmax and low Km.
Class II only in the liver and
Class III in all the tissues.
Class IV in stomach.
In gastric mucosa the first pass metabolism of alcohol starts. The ADH
present here has high affinity to alcohol and is higher in men , lesser in females and
elderly10.
In the liver the oxidizing capacity of the ethanol is maximum with ADH
having very high affinity and low Km value.
CH3CH2OH + NAD+ NADH + H+ + CH3CHO
Acetaldehyde is the metabolized product of ethanol by the action of alcohol
de-hydrogenase enzyme.
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The increase in the NADH causes the metabolic imbalance and acetaldehyde
is the potent causative factor for alcohol induced pathogenesis in humans.
Alcohol metabolism undergoes zero order  kinetics – 100 mg/ kg body weight /
hour. Km of ADH is 4 mg/ 100 ml.
MEOS (Mitochondrial Ethanol Oxidising System) :
Km of MEOS  is 50- 80 mg / 100 ml.
A small portion of alcohol is oxidized by cytochrome P450 – CYP2E1 the
enzyme in endoplasmic reticulum which is induced by alcohol.
Catalase :
The enzyme, in peroxisomes takes part in  less than 2 % of alcohol
metabolism. It requires hydrogen peroxidase for its action11.
Aldehyde dehydrogenase ( ALDH):
This enzyme is coded by 4 independent genes on 4 different chromosomes.
ALDH gene has two allelic forms ALDH 1 and ALDH 2. ALDH 2 has lower
activity when compared to ALDH 1.
14
EFFECTS OF ALCOHOL
 Acetaldehyde is the major causative factor for the pathophysiology of
alcoholic liver disease. Acetaldehyde  forms adducts with many protein and
impairs its function12 .
 The micro tubular function is disturbed due to the binding of acetaldehyde to
alpha – tubulin .This leads to fat accumulation in golgi apparatus of
perivenular hepatocytes.
 There is down regulation of microsomal triglyceride transfer protein (MTP)
which does packaging of TAG ( Triacylglycerols) and apo B into VLDL.
 Acetaldehyde inhibits PPAR – α ,a transcription factor, which regulates
mitochondrial , microsomal and peroxisomal fatty acid oxidation systems in
liver so that there is increase in free fatty acids in liver .
The overall effect of alcohol metabolism is the altered redox state, the increase
in NADH/ NAD ratio which impairs gluconeogenesis , decrease in the substrate flow
to TCA cycle ,inhibition of fatty acid oxidation  and increase in TAG synthesis.
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Hence alcohol acts as a potential hepatotoxin for the liver disease development
depending on the existence of cofactors like gender, polymorphism of alcohol
metabolizing enzymes, immunity, infection, nutrition and drug status9.
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PATHOPHYSIOLOGY OF ALCOHOLIC DISEASE
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MORPHOLOGY OF ALCOHOLIC LIVER DISEASE
STAGES
The first stage is the lipid droplet accumulation in the hepatocytes pushing the
nucleus to the periphery of hepatocytes. Starting with centrilobular distribution it
extends to the entire lobule.The fatty liver is large,soft yellow greasy organ now which
is a completely reversal phenomenon on abstinence of alcohol13.
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The second stage is the alcoholic hepatitis characterized by hepatocyte
swelling, necrosis with mallory bodies. Neutrophilic infiltrations along with
prominent activation of fibrosis which is due to stellate cell and portal tract fibroblast
activation. Starting from perivenular region it extends on with repeated bouts of heavy
alcohol intake. The liver is larger with visible nodules and fibrosis13.
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The final irreversible stage is evolution to cirrhosis. The cirrhotic liver is yellow
tan, fatty and large during earlier stages transforming into shrunken non fatty organ
at final stage. The fibrous septae are delicate  and extend through sinusoids from
central to portal regions13.
20
MELD SCORE
Chronic liver failure leads to multi organ dysfunction and early death. Chronic
alcoholism is one of the reason for chronic liver failure. Many studies have showed
increased morbidity and mortality in patients with chronic liver failure undergoing
surgical or interventional procedures12.
In view of categorizing and predicting the outcome of such procedures various
scoring systems were devised. Of which Child Pugh(CP) classification was more
prevalently used. The parameters used were serum bilirubin, prothrombin time,serum
albumin with two more clinical parameters like encephalopathy and ascites. Points
were given for each indices and based on the cumulating of points risk, stratification
is done. Even though CP classification is useful in cirrhotic patient undergoing
medical management and as well predicting postoperative outcome it has been not
sensitive in predicting short term outcome of morbidity (within 30 days) in cirrhotic
individuals12.
To overcome this deficit in scoring system MELD (Model for End-stage Liver
disease) score was introduced. Initially it was used to predict morbidity outcome in
patients with cirrhosis undergoing TIPS (Trans Jugular Intra Hepatic Porto systemic
Shunt) procedure.
The MELD is a numerical scale ranging from 6(less ill) to 40(gravely ill) used for
liver transplant candidates age 12 and older. It gives each person a score based on how
urgently the patient needs the liver transplant within the next 3 months. The patients
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score may go up or down over time, hence the score is assessed number of times while
on waiting list.Status I category or Highly urgent patient (acute liver failure).
Three easily measurable values i.e. serum bilirubin, INR and serum creatinine are
used. These values are entered in a formula and MELD score is arrived. Later MELD
score was extended to measure mortality risk in hospitalized and ambulatory patients
with cirrhosis. Its usefulness appears due to scoring irrespective of underlying disease
etiology. In 2002 UNOS (United Network of Organ sharing) has introduced a
modified MELD scoring system for organ allocation in patients with liver failure
awaiting liver transplant14.
The MELD score is calculated as follows :
MELD Score =   0.957 x Log e(creatinine mg/dL)   +  0.378 x Log e(bilirubin
mg/dL)   +  1.120 x Log e(INR)   +  0.6431
Multiply the score by 10 and round to the nearest whole number.
Laboratory values less than 1.0 are set to 1.0 for the purposes of the MELD score
calculation.
The maximum serum creatinine value in MELD score is set to 4.0 and values are
automatically interpreted according to recent dialysis.
MELD scoring is done for patients with age 12 and above. For patients with age less
than 12 PELD score is used14.
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BIO CHEMISTRY OF ZINC
Zinc is one of the most essential trace element belonging to group 12 of the
periodic table . It has a relative atomic mass of 65.38 and 30 as its atomic number, is
found abundant in the human body15,16.
It is considered to be a master hormone  in the process of cell division and
growth. The total adult body content is 2.25gms and distributed more in the muscle
(55 %)  followed by bone( 30%)  .The intake of zinc recommended daily is 14 mg per
day for men and 9 mg for women .
Dietary sources : It is  present in red meat , fish ,wheatgerm and wholebran in large
quantities.
Absorption :
Absorption of zinc occurs throughout the intestinal tract mainly in jejujum.
The efficiency of zinc  absorption depends on the amount of intake. It is regulated by
intake and as well by endogenous loss of zinc from intestinal fluids.
Transport of zinc 15,16:
Zinc transportation is through significant transporters the ZiP(15) and ZnT(9).
ZiP type of transporters increase the intracellular concentration by promoting uptake
while ZnT mobilises zinc out of cell. Zinc absorbed is taken by portal  vein to liver
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and is incorporated in metalloenzymes ,followed by plasma proteins.( 80% to albumin
and 20% to alpha -2 macroglobulin ). Zinc content is high in prostate ,semen ,retina.
Excretion :
urine excretion per day is 0.5 mgs Faeces excretion per day is 10 mgs. The  total
intake equals the daily output.
Functions of zinc15 :
It constitutes the major part of many enzymes like
 Aldehyde dehydrogenases
 Carbonic anhydrase
 Alkaline phosphatase
 RNA and DNA polymerases
 Thymidine kinase carboxy peptidases etc.,
24
 Zinc fingers :
The histidine and cysteine part of protein domain will have the tetrahedral zinc
atoms and form zinc fingers and they have a role as transcription factors in
developmental biology16.
 Zinc has interaction with vitamin A in producing retinal binding protein and is
involved in the activity of retinol dehydrogenase.
 Zinc is involved in ammonia metabolism, its deficiency impairs the function of
urea cycle enzyme ornithine transcarbamylase.
 Zinc is very essential in taste acuity, normal membrane structure and function.
 Zinc is required for the maintenance of spermatogenesis and motility.
 Zinc plays a role in nucleic acid metabolism , synthesis of collagen hence it
plays a important in wound healing.
 Zinc plays a role in innate and adaptive immunity .
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 Zinc  inhibits  TNF –alpha  activity and attenuates oxidative stress by reducing
the production of reactive oxygen species.
Role of zinc in liver function2:
Zinc protects intestinal barrier function and prevents endotoxinemia, reduces
pro-inflammatory cytokine production thereby preventing liver injury. Zinc
suppresses alcohol elevated CYP 2E1 activity and increases ADH activity in liver.
Zinc prevents alcohol induced decrease of GSH concentration and increases
glutathione reductase activity thus suppressing alcohol induced oxidative stress.
Zinc attenuates alcoholic hepatitis and the m-RNA levels of TNF, FasL, FAF-
1,Caspases,the factors associated with apoptosis of hepatocytes. Supplementation of
zinc attenuates fibrotic changes. Hence zinc has wide functional ability in
hepatoprotective mechanisms.
Laboratory assessment of zinc :
Sample recommended include fasting serum or plasma ,urine ,leukocytes and
hair . A reference interval for serum zinc is 80 -120 µg/dl or 12 -18 µmol/L. For urine
zinc 0.2 to 1.3 mg /24 h. Circadian changes include high values in the mornings than
evening and post prandial decrease17.
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ALKALINE PHOSPHATASE
Alkaline Phosphatase E.C.No 3.1.3.118;Ortho phosphoric mono ester
phosphohydrolase.
Optimum pH for activity is 8.4 -10
Activators : Mg2+ ,Co2+ and Mn2+
Inhibitors : Citrate,Borate,Phosphate,Oxalate and EDTA.
Zinc is a constuent metal ion. The correct ratio of magnesium/zinc ions is necessary
to attain optimal activity of the enzyme.
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Alkaline phosphatase are group of enzymes that take part in hydrolysis of
phosphates at higher pH. Contribution of this enzyme is mostly from liver, bone,
placenta, least from intestinal epithelium and kidney19.
Hepatic alkaline phosphatase is most densely represented near the canalicular
membrane of the hepatocyte19.The response of the liver to any form of biliary tree
obstruction induces the synthesis of ALP by hepatocytes.
An experimental study shows one of the function of enzyme alkaline
phosphatase in liver cell membrane  is to hydrolyse phosphorylcholine and so that
choline can cross canalicular membrane into  the bile20.
When cholestatsis happens due to intrahepatic origin bile secretion from
hepatocyte to canaliculi is impeded which leads to regurgitation of the enzyme in to
plasma which is reflected as increase activity21.
Increased activity of alkaline phosphatase with increased  γ- GT in serum
almost always reflects etiology of hepatobiliary origin21.
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Accordingly, diseases that predominately affect hepatocyte secretion (e.g.,
obstructive diseases) will be accompanied by elevations of alkaline phosphatase
levels. Bile-duct obstruction, primary sclerosing cholangitis, and primary biliary
cirrhosis (PBC) are some examples of diseases in which elevated alkaline phosphatase
levels are often predominant over transaminase level elevations22.
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REVIEW OF JOURNALS
Craig Mc Clain et al, Annals of Hepatology (1) 2008,5-15.
The author delivers a concise review about the treatment of alcoholic liver
disease. The review states that nutritional supplementation is a benefit along with
abstinence from alcohol, smoking and weight loss. Pentoxiphylline being beneficial
in alcoholic hepatitis. Complementary agents like zinc,milk,SAM have great
therapeutic rationale. Liver transplantation is the only solution for end stage liver
disease23.
 Ferdousi,ahia et al,Journal of Medical Biochemistry 2012(5(2)) 44-47.
The study evaluates the zinc status in patient with liver cirrhosis.The
study has shown a significant lower plasma zinc level in cirrhotic patients.When
compared with normal controls estimated by colorimetry the age and gender related
bias were prevented by taking in to account the similar range of age24.
 Ana.C.R Schneider et al,Journal de Pediatria 2009 , 85-04/359-364
The study has been conducted to assess zinc status in paediatric cirrhotic
patients. The author has investigated the association results obtained from atomic
absorption spectro photometry. Anthropometric measures have also been included to
relate to the level of zinc.The results were prevelance of hypozincemia in 43% of
patients with cirrhosis.There is no association between anthropometric levels and zinc
levels25.
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 Y.Takumme,et al Alimentary pharmacology and therapeutics – 2010: 32:
1080-1090.
This is a clinical trial  where the study has evaluated the changes in the
physical component scale and mental component scale of alcoholic patients with HE
and control population. The author has also concluded that zinc supplementation has
decreased HE grade , blood ammonia levels and improved CP scale.  It was not
significantly associated with changes in MCS26.
 Krenitsksy  et al  ,nutrition issues in gastroenterology series 6, June 2003
The article address certain strategies to overcome hurdles in the nutritional
delivery in the population of hepatic failure .The author has stated the significance of
zinc in the function of liver in detoxifying and improving encephalopathy scores27.
 Kaushikkar, et al  Indian Medical Gazzete–feb 2013/74-78
The author has analysed serum zinc and albumin levels in cirrhotic
patients and controls and has stated a significant decreased in zinc and albumin  with
significant P value <0 .00128.
 Mohammad zhou et al nutrition in clinical practice 2012.
The article states  about zinc and its significance in liver function,
manifestations of its deficiency and emphasizes on zinc supplementation to stabilize
gut barrier function ,decreasing the endotoxins and oxidative stress2.
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 Yang et al,1991 June;22(2);201-3
The author introduces a micro method for zinc and copper estimation by
concentrating peripheral blood by  wave oscillopolarography. The author states the
method to be superior and simple compared to atomic absorption spectrophotometry29.
 Makino et al Clin .ChemActa 1982 mar 26;120(1);127-135
The author introduces a colorimetric method for accurate determination of
serum zinc .The within day precision (cv) are in range of 0.3 to 3.5% and 1.9 -3.1
%.The author had obtained a good correlation between colorimetry and AAS30.
 Makino et al Clin Chem Acta 1999 Apr ;282 (1-2)65 -76
A simple and sensitive assay of zinc in serum using cationic porpyrin .The
author has introduced a method that has a cationic porphyrin ( 4-N tri methyl amino
phenyl porphinetetratoluenesulphonate salt .7 iodo 8 hydroxyl quinolone 5 sulphonic
acid (ferron )as a accelerator31.
 Beckett et al  Ann Clin Biochem 2009 July ;46 322-6
The author has made a comparison between two method calorimetric and AAS
and has concluded that the results have systematic and fixed bias and hence AAS to
be superior for determination of copper and zinc32 .
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 Arnand j et al Clinbiochem 1993 trial on determination of copper and zinc
feb;26(1)
The author has conducted a inter-laboratory trial on determination of copper
and zinc by two different methods.The author states sensitivity and linear range to be
good in calorimetry and also correlated satisfactorily33.
 Patrick et al Hepatology 2007;45;797-805
The author in this article reviews the MELD score, compares with other scores
and depicts the strength and limitations of the score .He also suggests for right method
of analysis of various objective variables taken into account. He suggests for better
refinement of the score in future34.
 Azam hyder et al European journal of experimental biology 2013,3(2)280-284
The author has analysed various enzyme panels in liver disease by standard
methods and has concluded that AST,ALT,ALP,GGT were significantly raised in
patients than in controls with significant p’ value(<0.001)35.
 Kareweissman et al the American journal of clinical nutrition june 1985/
1214-1219
The author has analysed serum zinc and ALP during zn supplementation in
patients with proven zinc deficiency and elderly and normal controls. Zinc and ALP
levels rose after zinc therapy initiation ,decreased after stoppage . Hence he has
suggested serial serum Zn and  ALP estimations could be a valid tool in diagnosis of
zinc deficiency36.
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 Xinqinkang et al  Hepatologyoct 2009 Vol 50/1241-51
The author has done an elaborative study molecular diagnostic wise using PCR
immunoblotting and has stated that zn supplementation normalizes  alcoholic steatosis
and reactivates TNF –alpha and PPAR –alpha on zinc availability and oxidative
stress37.
 Han-chieh Lin et al  Liver transplant 12;65-71 2006
The author has proposed a modified CTP score and compares to be better than
original one and MELD score38.
 J.C.Smith et al ClinChem 25/8 1478-1491(1979)
The author has concluded the direct dilution method when compared to
calorimetry and induction coupled plasma emission to be accurate ,precise ,free of
specific iron interference and simple39.
 Kuldipsingh et al international journal of research in health science Oct - Dec
2013- Vol 3 issue 1
The author has illustrated the various liver function tests under various sub
heads and established the need for the whole profile of LFT in liver diseases40.
 Matsuoka et al, Journal of Clinical Biochemistry.Nutrition., 45,Page 292-
303,Nov 2009
The study is about the effect of zinc and BCAA granules supplementation
especially in HCV related carcinogenesis of liver41.
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MATERIALS AND METHODOLOGY
This is a case control study conducted during the period  from january 2015 to
june 2015.Prior approval was obtained from the Institutions Ethical Committee.
The study involves two groups, Group – I with 50 healthy members as control,
recruited from master health checkup at Stanley Medical College and neighborhood.
Group – II with 50 cases of pre-diagnosed alcoholic liver disease from Medical
Gastro Enterology Department, Stanley Medical College Hospital.
Written consent with explained protocol was obtained from both groups .
Inclusion criteria :
Patients diagnosed to have ethanol related decompensated liver disease with or
without portal hypertension.
Exclusion criteria :
 Patient with non-alcoholic liver disease.
 Patients on zinc supplementation.
 Patients with malabsorption syndromes.
 Patients who had undergone intestinal resection procedures.
 Patients with co-morbid conditions like diabetes mellitus, malignancy, renal
failure, known viral disease and on treatment with steroids, hormones.
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Sample Collection and Preparation:
5 ml of venous blood from ante-cubital vein (over night fasting sample) was
collected under strict aseptic precautions. Serum samples were separated by
centrifugation at 2000-2500 rpm for I5 minutes and used for analysis. Samples were
stored  at -20 ⁰C until analysis.
Estimation of Zinc :
Colorimetric method – end point
Principle :
Zinc forms a colored complex when reacting with a specific complexant 5 – Br-
PAPS. The intensity of  color formed is proportional to the amount of zinc present in
the sample, measured at 560 nm
Sample :
Serum,plasma ,seminal fluid and urine .
Reagents :
R1 Buffer Good pH 8.6 0.2 mol/L
R2 Color 5- bromo PAPS 1.1mmol/l
R3 Reducing substance
ascorbic acid
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ABSORBANCE OF ZINC STANDARDS
Reagent Blank = 0.105
Concentration of
zinc(µg/dL)
Absorbance Standard – blank
Absorbance
50 0.166 0.061
100 0.227 0.122
200 0.345 0.240
0
0.03
0.06
0.09
0.12
0.15
0.18
0.21
0.24
0.27
0.30
STANDARDISTION OF ZINC
COLORIMETRIC METHOD WITH 5-Brom-PAPS
Scale :-
X axis - Concontration
of zinc standand
Y axis - Optical
density
x axis 1 cm - 25 mg/dl
y axis 1 cm - 0.03
O
PT
IC
AL
DE
N
SI
TY
25
CONCENTRATION OF ZINC STANDARD(mg/dl)
50 75 100 125 150 175 200 225 250
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Calibration : The zinc calibrator value is verified by NIST traceable standard.
Zinc calibrator 200 µg
Preparation :
Working reagent: R3 is mixed with r1.mix well stable for 30 days at 2-8 days.
Procedure:
Reagents at room temperature
Blank Standard Sample
Working reagent 1.0 1.0 1.0
Distilled water 50 - -
Standard - 50 -
Sample - - 50
Mix and absorbance is read at 560nm against blank.(A1)
Blank Standard Sample
R2 100 100 100
Mix and read the absorbance of sample (A2).
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Calculation :
(A2-A1)/(A2-A1) X 200 = CONC of ZINC
Conversion factor : µg/dl X 0.153 = µmol/L
Reference valves:
Serum - 68-107 µg/dl
Centrifuged seminal fluid – 2-10 mg/dl
24 hrs – urine 150-1200µg/L
Measuring  range : 4µg/dl – 2000 µg/dl
ESTIMATION  OF CREATININE
Serum creatinine is more specific and sensitive indicator of renal function along with
urea .
Principle :
Creatinine + H2O Creatine
Creatine+ H2O Sarcosine + Urea
Sarcosine + O2+ H2O Glycine + HCHO+4 H2O2
2H2O2 + 4 –AA+ TOOS Quinone pigment +4 H2O
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Reagent :
Creatinine R1
Creatinase ,Sarcosine oxidase,TOOS
Creatinine R2
Creatinase
Peroxidase
4-AA
Creatinine standard concentration-2 mg/dl
The  reagent is linear up to 200 mg/dl
Normal range :
Serum  Male : 0.6 – 1.1 mg/dl
Female : 0.5 – 0.8mg/dl
Urine Male : 1070-2150 mg/ dl
Female : 769 – 1200 mg/dl
System parameters:
Mode of reaction Endpoint
Slope of reaction increasing
Primary wavelength 546nm
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Secondary wavelength 630nm
Temperature 37⁰C
Std conc . 2mg/dl
Linearity 200 mg/dl
Blank Reagent
Incubation time 10 min
Sample vol 10 µl
R1 450µL
R2 150 µL
Cuvette 1 cm light path
Procedure:
Blank Calibrator Sample
Reagent µl 450 450 450
Calibration 10µl
Sample 10µl
Mix and incubate for 5 min at 37 ⁰C. Measure the absorbance.
Calculation :
Creatinine concentration = (Abs of sample /Abs of standard) X Std concentration
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ESTIMATION OF PROTHROMBIN TIME
The prothrombin time is an indicator of the extrinsic pathway of coagulation
cascade.
Principle :
Tissue  thromboplastin in the presence of calcium activates extrinsic pathway
of human blood clotting system. When thromboplastin reagent is added to citrated
plasma , clotting is initiated and clot forms. Activation time is proportional to the
concentration of clotting factors.
Reagent  :
Tissue factor ( rabbit origin )
Calcium
Preservative
Stabilizers
Pack contents:
PT reagentsR1
Buffered trisodium citrate ( 0.109)
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Normal range :
Prothrombin  time - 11—15 sec
INR value – 0.8 – 1.5
Sample collection :
Citrated plasma,mix gently 9 parts blood and  1 part of 3.2% trisodium citrate ,
centrifuge for 15 min at 3000 rpm to get platelet free plasma .
Procedure:
Pre warm the reagent at 37 c for 10 min
Pipette 100µl of  plasma  incubate for 3 min
Add 200µl and simultaneously  start timer and watch for clotting to occur, note time
immediately, it is the prothrombin time .
Turbid ,lipaemic and hemolysed samples are to be avoided.
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ESTIMATION OF BILIRUBIN
METHODOLOGY : Diazo method by Lee and Pearlman
Principle :
Sulphanilic acid reacts with sodium nitrate to form diazotized sulphanilic acid.
Total bilirubin reacts with diazotized sulphanilic acid in the presence of DMSO to
form azobilirubin.
Reagent Composition:
Total bilirubin reagent - 2 x 50 ml
Sulphanilic acid - 28.9mol/L
HCl - 165mmol/L
DMSO - 7mmol/L
Total Bilirubin Activator - 1x4ml
Direct bilirubin agent - 2x50ml
Sulphanilic acid - 28.9mmol/L
HCl - 165mmol/L
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Direct Bilirubin activator - 1x4ml
Bilirubin artificial standard - 1x4ml
Total bilirubin standard concentration - 10mg/dl
Direct bilirubin standard concentration - 7.5mg/dl
Storage and Stability  :
The reagents are stable when stored at right temperature.
The standard and activator should be stored at 2-80 C.
Linearity:
This reagent is linear up to 20mg/dL.If the concentration is greater than linearity
(20mg/dl) dilute the sample with normal saline .
Multiply the result with dilution fraction.
Normal range :
It is recommended that each laboratory establish its own reference values.
The following value may be used as guideline.
Total bilirubin up to 1.2mg/dl
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Direct bilirubin up to 0.4mg/dl.
Preparation and Stability of Reagent :
Reagents are ready to use.
Avoid direct exposure of reagent to light.
Sample:
Serum/Plasma (without hemolysis)
SYSTEM PARAMETER
Mode of Reaction End point
Slope of Reaction Increasing
Wavelength 546-532 nm
Temperature 300C
Factor(Total) 20.5
Factor(Direct) 16
Blank Sample blank
Linearity 20 mg/dl
Reaction time 5 mins
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Sample volume 50 µL
Reagent volume 1000µL
Activator 20µL
Cuvette 1 cm light path
LABORATORY PROCEDURE
Total Bilirubin Direct Bilirubin
Sample
blank
Test Sample blank Test
T.Bilirubin
reagent
1000µL 1000µL - -
D.Bilirubin
reagent
- - 1000µL 1000µL
Activator(T/D) - 20µL - 20µL
Serum 50µL 50µL 50µL 50µL
Mix well and incubate for 5 minutes. Measure the absorbance of the sample
against sample blank at 546 or 532 nm.
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CALCULATION:
Total Bilirubin =OD of test-od of sample blank x Factor
Direct Bilirubin =OD of test-od of sample blank x Factor
With artificial standar
Total bilirubin Concentration = × 10
Direct bilirubin Concentration = × 10
ESTIMATION OF GAMMA –GLUMATYL
TRANSFERASE (GGT),
IFCC Method ,Kinetic
Methodology:
The GGT-Soluble substrate method(GGT-SS), GGT present in the sample transfers
the glutamyl group from the substrate to glycylglycine to form glutamyl
glycylglycine and 5-amino-2-nitrobenzoate.
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Principle:
L - γ - glutamyl – 3 – carboxy – 4 – nitranilide + Glycylglycine
GGT
L - γ - Glutamyl glycylglycine + 5 – amino - 2 – nitrobenzoate
REAGENT COMPOSITION
REAGENT 1 : GGT Reagent
ACTIVE INGREDIENTS CONCENTRATION IN THE TEST
Tris buffer(pH8.2±0.1 at 200C 100 mmol/L
Glycylglycine 100 mmol/L
L - γ - glutamyl – 3 – carboxy – 4 –
nitranilide
2.9 mmol/L
REAGENT RECONSTITUTION
Allow the reagent bottle and Aqua-4 to attain the room temperature15-300C.Add the
amount of Aqua-4 contents of each vial. Swirl to dissolve
The reagent is stable for at least 21 days when stored at 2-80C or for 5 days at room
temperature of 15-300C. Discard with reagent greater than 0.7 at 405nm(1 cm) when
read against a distilled water blank.
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SAMPLE :
Unhemolysed serum and plasma (Heparin or EDTA) are suitable for use with this
method.Anticoagulants like EDTA will interfere with the assay and hence  not be
used.
GGT is stable for 7 days when stored at 2-80C.
ASSAY PARAMETERS:
Mode Kinetic
Wavelength(nm) 405
Sample Volume(µl) 50/100
Reagent Volume(µl) 500/1000
Lag time(sec) 30
Kinetic interval(sec) 60
No. of readings 3
Kinetic factor 1158
Reaction
Temperature(⁰C) 37
Reaction Duration Increasing
50
Normal Low(IU/L) 0
Normal High(IU/L) 50
Linearity Low(IU/L) 0
Linearity High(IU/L) 450
Absorbance(Max) 0.700
Blank with Water
Units IU/L
ASSAY PROCEDURE
Volumes
Working reagent 1000µl
Test 100µl
CALCULATION
The general formula for converting absorbance change into International Units (IU)
of activity is = (∆ / ) . 10.
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T.V = total reaction volume in µl
S.V = sample volume in µl
Absorptivity = millimolar absorptivity of L- γ -glutamyl – 3 – carboxy – 4 –
nitroanilide 405 nm = 9.5
P = cuvette lightpath (cm) = 1 cm
Activity of GGT at 37⁰C (IU/L) = ( ∆ A 405 / min) X Factor (1158)
LINEARITY
Upto 450 IU/L
NORMAL VALUES (Reference for guidelines)
TEMPERATURE MALE FEMALE
37⁰C ≤ 50 U/L ≤ 30 U/L
30⁰C ≤ 39 U/L ≤23 U/L
25⁰C ≤ 17 U/L ≤ 17 U/L
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PERFORMANCE DATA
PrecisionWithin run
LEVEL I LEVEL II
Number of samples(n) 20 20
Mean 20 67
S.D 0.41 1.00
C.V(%) 2.05 1.49
Between run
Number of samples(n) 20 20
Mean 22 67
S.D 1.80 2.05
C.V(%) 8.18 3.06
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ESTIMATION OF ALBUMIN
Method : BCG
TEST PRINCIPLE
In the presence of bromocresol green at a slightly acidic pH serum albumin
produces a color change of the indicator from yellow-green to green-blue. The
intensity of the blue-green color is proportional to the concentration of albumin in the
sample.
TEST PARAMETERS
Method Colorimetric, Endpoint, Increasing
reaction, BCG
Wavelength 546 nm
Temperature 37⁰C
Sample Serum, heparin or EDTA
Linearity Up to 6 g/dL
Sensitivity The lower limit of detection is 0.2 g/dL
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REAGENT COMPOSITION
Citrate buffer pH 4.2 30 mmol/L
Bromocresol green 0.26 mmol/L
MANUAL TEST PROCEDURE
Blank Std./Cal. Sample
Reagent 1000µL 1000µL 1000µL
Sample - - 10µL
Std./cal. - 10µL -
Dist.water 10µL - -
Mix, Incubate for approx. 10 min at 20-25⁰C/37⁰C and
read absorbance against reagent blank within 60 min.
CALCULATION
Albumin (g/dL) = ∆∆ / X Conc.of Std/Cal (g/dL)
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REFERENCE RANGE
g/dL µmol/L
Adults 3.5 – 5.2 507 – 756
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ASAT
MDH
ESTIMATION OF SGOT
Method :
IFCC method
Optimized UV test according to IFCC
Principle
L-Aspartate + 2-Oxoglutarate L-Glutamate + Oxaloacetate
Oxaloacetate + APADH( NADH analogue) + H⁺ L-Malate + APAD (
Oxidized NADH analogue)
Reagents
R1 TRIS  pH 7.65 100 mol/l
L-Aspartate 250 mmol/l
MDH(Malate
Dehydrogenase)
≥ 550 U/l
LDH (Lactate
Dehydrogenase)
≥ 700 U/l
R2 2- Oxoglutarate 10 mmol/l
APADH(NADH
analogue)
0.20 mmol/l
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Mix R1 and R2 (800 µl R1 + 200 µl R2) along with sample at the time of testing.
Specimen
Unhemolysed freshly collected serum/ EDTA plasma (morning samples are
preferred)
Test Procedure
Take the following in a clean glass test tube
R1 0.8 ml
R2 0.2 ml
Serum/Plasma 100 µl
Mix well  and after 60 seconds incubation, measure the change in optical
density per 60 seconds during 180 seconds against distilled water at 340 nm as
follows
A₀ - Exactly after 60 seconds
A1, A2, A3 - Exactly after every 60 seconds for 180 seconds
Activity of SGOT in IU/L
At 340 nm in IU/L    = Abs/min x 1975
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System Parameters
Reaction type Kinetic
Reaction Direction Decreasing
Wavelength 340 nm
Flow cell temp 37⁰C
Zero setting with Distilled water
Delay time 60 secs
Kinetic interval 60 secs
No.of readings 4
Reagent volume 800 µl R1 + 20 µl R2
Sample volume 100 µl
Factor 1975
Linearity 500
Units IU/L
Low normal 0.00
High normal 40.0
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ALAT
MDH
ESTIMATION OF SGPT
IFCC method
Method :
Optimized UV test according to IFCC (International Federation of Clinical
Chemistry and Laboratory Medicine) Modified
Principle
L-Aspartate + 2-Oxoglutarate                        L-Glutamate + Pyruate
Pyruate + APADH( NADH analogue) + H⁺ L-Lactate + APAD (
Oxidized NADH analogue)
Reagents
R1 TRIS  pH 7.5 250 mol/l
L-Alanine 500 mmol/l
LDH (Lactate
Dehydrogenase)
≥ 5000 U/l
R2 2- Oxoglutarate 20 mmol/l
APADH(NADH
analogue)
0.25 mmol/l
Azide 0.1%
Mix R1 and R2 (800 µl R1 + 200 µl R2) along with sample at the time of testing.
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Specimen
Unhemolysed freshly collected serum/ EDTA plasma (morning samples are
preferred)
Test Procedure
Take the following in a clean glass test tube
R1 0.8 ml
R2 0.2 ml
Serum/Plasma 100 µl
Mix well  and after 60 seconds incubation, measure the change in optical
density per 60 seconds during 240 seconds against distilled water at 340 nm as
follows
A₀ - Exactly after 60 seconds
A1, A2, A3 - Exactly after every 60 seconds for 240 seconds
Activity of SGPT(ALT) in IU/L
At 340 nm in IU/L    = Abs/min x 2225
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System Parameters
Reaction type Kinetic
Reaction Direction Decreasing
Wavelength 340 nm
Flow cell temp 37⁰C
Zero setting with Distilled water
Delay time 10 secs
Kinetic interval 60 secs
No.of readings 5
Reagent volume 1 ml
Sample volume 100 µl
Factor 2225
Linearity 500
Units IU/L
Low normal 0.00
High normal 48.0
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ALP
ESTIMATION OF ALKALINE PHOSPHATASE
AMP Buffer/IFCC Method
PRINCIPLE
p-Nitrophenyl phosphate analogue + H₂O p-Nitrophenol + Phosphate
ACTIVE INGREDIENTS OF WORKING AGENT
AMP pH 9.7  3.5 mol/l
Magnesium chloride 0.6 mmol/l
p-Nitrophenyl phosphate analogue 0.070 mmol/l
Sodium azide 0.10%
Zinc sulphate 0.3 mmol/l
Specimen
Specimen is Unhemolysed serum .Samples are stable for a week at 2 - 8⁰ C
and for a month at -10⁰C.The ALP activity in serum stored at 2 - 8⁰ C increases with
time.
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Test Procedure
R1 0.8 ml
R2 0.2 ml
Serum/Plasma 25 µl
Mix well  and aspirate. Measure the change in optical density against distilled water
at 405 nm as follows
A₀ - Exactly after 60 seconds
A1 - Exactly after every 60 seconds
Activity of ALP activity in IU/   = ∆ A/min x 320
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System Parameters
Reaction type (Mode) Kinetic
Reaction Direction Increasing
Wavelength 405 nm
Flow cell temp 37⁰C
Zero setting with Distilled water
Delay time 60 sec
Kinetic interval 60 secs
No.of readings 5
Reagent volume R1 0.8 ml + R2 0.2 ml
Sample volume 25 µl
Factor 3200
Linearity 1000
Units IU/L
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Reference range
20- 50 years       Males: 53 – 165 U/L          Females : 42 – 136 U/L
≥ 60 years           Males : 56 – 136 U/L         Females : 53 – 160 U/L
In  children the value will be higher than adults i.e 350 – 585 IU/L
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RESULTS AND STATISTICAL ANALYSIS
The study population consisting of 100 subjects – 50 controls and 50 cases.
Statistical software SPSS was used to analyze the statistical data. The distribution of
age among Group I & II were shown in table 1. Estimation of mean and standard
deviation done for each group. Data expressed as mean +/- standard deviation.
Students unpaired ‘t’ test is used to compare the means between two
independent groups. F test is applied between the study variables to know whether ‘t’
test can be applied to study the parameters and also which type of ‘t’ test –either equal
variance or separate variance  unpaired ‘t’ test can be applied in this study. Pearson
coefficient of correlation is used to estimate the degree of association between two
quantitative variables. A p-value of <0.001 will be considered as statistically
significant.
Age group wise comparison of mean values of zinc and alkaline phosphatase
were done. Graphical representation was done using scatter diagrams.
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Table 1
Age distribution among cases and controls
Group N Mean age(years) Standard
deviation
Student ‘t’test
Case 50 42.79 9.68 p value > 0.05
not significant
Control 50 44.8 8.64
Table 2
Age distribution among cases and controls
Case Control
20-35 11 10
36-50 25 26
51-75 14 14
Total 50 50
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Table 3
Mean and standard deviation of Variables in groups
Variable Mean ± S.D P value
Cases Control
T.bilirubin 16 ± 7.4 0.5 ±   0.2
< 0.001
significant
Albumin 2.3  ± 0.8 4.8 ±    6.2
Globulin 3.2 ±   0.8 2.5  ±    0.4
AST 160 ±   55.4 18.6  ±   11.1
ALT 71  ±    62 10.8  ±    5.8
GGT 130.2 ±   112 9.6   ±    5.4
Alk.phos 234  ±  191.6 89.2±28.4
Creatinine 1.2±1.02 0.7±0.1
INR 1.4±0.4 0.9±0.06
Prothrombin  time 17.5± 3.9 11.2±0.6
Zinc 47.5±19.7 98.8±26
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Comparison of zinc values between cases and controls
Serum zinc in µg /dl
PEARSON’S CORRELATION
The sign of ‘r’ denotes the nature of association
+ sign – Positive correlation
- sign – Negative correlation
The value of ‘r’ denotes the strength of association
‘r’ lies between +1 and -1
P value < 0.05 indicates significant association
0
20
40
60
80
100
120
cases controls
serum zinc
zinc
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Table 4: Correlation of serum zinc and alkaline phosphatase in alcoholic liver
disease patients
Variables Pearson’s
correlation
coefficient
(r)
Significance
(p)
Interpretation
Zinc
vs
Alk.phos
-0.06 <0.001 Significant &
negative
correlation
Scatter diagram
Correlation of zinc and alkaline phosphatase
X- axis Zinc µg/dl
Y-axis Alk Phos U/L
0
10
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50
60
70
80
90
100
0 200 400 600 800 1000 1200 1400 1600
Zinc Vs ALP
Zinc
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Table 5 : Correlation of serum zinc and albumin in alcoholic liver disease patients
Variables Pearson’s
correlation
coefficient
(r)
Significance
(p)
Interpretation
Zinc
vs
Albumin
0.174 <0.001
Significant &
positive correlation
Scatter diagram
Zinc in µg/dl ,albumin in g/dl
y = 0.0155x + 2.6161
R² = 0.065
0
1
2
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6
0 20 40 60 80 100
alb
um
in
zinc
Zinc Vs Albumin
Albumin
Linear (Albumin)
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Table 6 : Correlation of serum zinc and duration of disease in alcoholic liver
disease patients
Variables Pearson’s
correlation
coefficient
(r)
Significance
(p)
Interpretation
Zinc
vs Duration of
alcohol intake -0.603 < 0.001
Significant &
negative
correlation
Scatter diagram
Alcohol duration in years
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Table 7: Correlation of serum zinc and MELD in alcoholic liver disease patients
Variables Correlation
coefficient
(r)
Significance Interpretation
Zinc
vs
MELD
-0.185 < 0.001
Significant &
negative
correlation
Scatter diagram
zinc µg/dl
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Zinc Vs MELD
MELD
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Table 8 : Correlation of serum zinc and GGT in alcoholic liver disease patients
Variables Correlation
coefficient
(r)
Significance
(p)
Interpretation
Zinc
vs
GGT
-0.301 <0.001
Significant &
negative
correlation
Scatter diagram
GGT U/L
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Table 9 : Correlation of MELD and Duration of alcohol in alcoholic liver disease
patients
Variables Correlation
coefficient
(r)
Significance
(p)
Interpretation
MELD
Vs duration of
alcohol
0.275 <0.001
Significant &
positive
correlation
Scatter diagram
Duration of alcohol in years
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MELD  Vs duration of alcohol
MELD
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DISCUSSION
The present study results demonstrate that higher percentage of patients with
alcoholic liver disease have low serum zinc levels compared to normal subjects.
Ferdousi et al has evaluated the zinc status in patient with liver cirrhosis and has shown
significant lower plasma zinc levels24.
Low levels of zinc in alcoholic liver diseases can be attributed to zinc bound to
albumin fraction which is decreased in liver disease. The anorectic effect of alcohol
decreases zinc uptake, and also the diuretic effect of alcohol can cause increase loss
of zinc in urine42.
In the present study the comparison between all the parameters of liver function
tests show uniform significance between cases and controls.
Azam et al has analyzed various enzyme panel in liver disease and has found
increased levels of liver enzymes in various states of liver disease35.
In our present study there is a significant increase in the levels of GGT and ALP
among cases. This increase can be related to chronic alcoholism and obstruction.
In this study there is a decrease in serum albumin levels among cases when
compared to controls .This is explained by the derangement of synthetic functions in
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chronic liver disease9. Few cases show abnormal coagulation parameters like
prothrombin time and INR which are increased.
Weismann et al has analysed ALP status in zinc deficient patients of
acrodermatititis enteropathica and elderly, as zinc is the cofactor for ALP, and has
found ALP levels decreased when zinc levels went down36.
In the present study there is an increased alkaline phosphatase level in spite of
hypozincemia among cases and this can be attributed to the obstruction that occur in
the later stages of cirrhotic liver.
The karl pearsons correlation coefficient between serum zinc and alkaline
phosphatase showed negative association and trivial correlation.
A significant and negative correlation was found between zinc and duration of
the alcohol intake. A significant and negative correlation was seen between zinc and
MELD score .This explains that the decrease in the trace element zinc is related to the
duration of alcohol intake and progression of the disease.
A significant and positive correlation was found between serum zinc and serum
albumin levels. The study by Kaushik kar et al has analyzed the same and had stated
a significant p value < 0.001 .This attributes to the bound nature of zinc to albumin28.
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A significant and positive correlation was analyzed between duration of alcohol intake
and MELD score. This clearly shows the contribution of alcohol as a hepatotoxic agent
to worsen the condition of the patient.
Further study with larger sample size, estimation of urinary levels of zinc, tissue
zinc levels, use of gold standard AAS for estimation of zinc are needed to exactly
evaluate the status of zinc in these patients and supplementing with zinc to bring down
the severity of the disease.
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CONCLUSION
In conclusion, the present study reflects the decrease in serum zinc levels and
elevated alkaline phosphatase levels in patients with alcoholic liver disease. The
significant statistical data provides us a strong rationale for evaluating the zinc status
along with the routine liver function profile  and also supports the supplementation of
zinc to patients with alcoholic liver disease.
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MASTER CHART – CONTROLS
S.No Age Sex Zinc
µg/dL
Albumin
g/dL
Globulins
g/dL
ALP
U/L
T.Bilirubin
mg/dL
SGOT
U/L
SGPT
U/L
GGT
U/L
PT
sec
INR Creatinine
Mg/dL
1 42 M 89 4.2 3 65 0.9 45 21 5 10.5 0.9 0.6
2 36 M 112 3.8 3 63 1 12 5 13 11.9 1.03 0.5
3 41 M 69 3.6 2.8 98 0.5 9 4 4 9.9 0.87 1
4 55 M 110 4.6 3 112 0.6 12 7 7 10.5 0.92 0.6
5 45 M 89 3.9 2 102 0.6 7 4 15 10.6 0.92 0.8
6 32 M 96 4 2 69 0.8 25 12 16 10.4 0.91 0.9
7 42 M 79 4 3 120 1.2 25 7 24 12 1.04 0.9
8 28 M 135 4.3 3 45 0.2 24 22 21 9.9 0.87 0.9
9 52 M 56 3.2 2.8 63 0.3 5 5 12 10.4 0.97 0.9
10 48 M 78 3 3 69 0.5 15 8 3 11.9 0.9 0.7
11 44 M 124 4.1 2.2 86 0.3 5 5 7 11.6 1.02 0.5
12 43 M 100 4.2 2 84 0.3 29 12 14 11.1 0.99 0.9
13 60 M 69 3.5 2.3 76 0.5 22 15 6 10.2 0.94 0.6
14 58 M 78 3.8 2 92 0.2 15 11 5 11.7 0.97 0.5
15 31 M 141 5 2.8 81 0.3 22 7 8 11.4 1.01 1.2
16 59 M 71 3.5 3.1 64 1 24 5 11 10.8 0.91 0.5
17 41 M 103 4.3 3 73 0.6 35 21 16 11.2 0.96 0.6
18 48 M 89 4 2.6 150 1.1 20 21 12 11.6 0.96 0.8
19 49 M 84 4 3 68 0.3 7 9 4 10.4 1.04 0.8
20 43 M 125 4.6 2.6 112 0.6 12 11 12 11 1.03 1
21 52 M 96 3.8 2.8 64 0.6 6 5 6 11.2 0.97 0.9
22 51 M 65 3 3 83 0.4 16 11 12 11.3 0.89 0.9
23 30 M 132 5 2.9 81 0.3 22 7 17 11.4 1.07 0.6
24 38 M 112 48 3 75 0.9 8 5 11 10.8 1.04 0.8
25 57 M 69 3 2.5 98 0.3 40 12 5 10.4 0.98 0.8
26 52 M 70 3.2 2.2 86 0.3 23 16 4 11.6 0.98 0.6
27 45 M 113 4.6 2.2 96 0.8 7 5 5 10.9 1 0.6
28 43 M 120 4.8 2.8 93 0.6 10 5 3 11.2 1.01 0.7
29 48 M 98 3.5 2 150 0.3 23 19 6 11.6 1.02 0.9
30 49 M 104 4 2.5 114 0.5 12 11 4 10.7 0.96 0.5
31 41 M 109 4 2.2 105 0.5 14 14 11 12 0.93 0.5
32 29 M 132 5 2.3 65 1 29 13 24 12.3 1.04 0.5
33 36 M 100 3.6 2 95 0.3 7 5 15 12 0.97 0.8
34 44 M 98 3.9 2.6 102 0.5 5 5 8 11.2 1 0.6
35 58 M 71 3.3 2 52 0.5 44 16 11 10.9 1.04 0.6
36 38 M 140 5.2 2.3 94 1.2 23 11 6 11.4 0.96 0.7
37 45 M 99 4 2.3 65 0.3 12 7 16 11.6 1.07 1
38 46 M 95 4.2 2 85 0.3 10 7 16 11.5 1.09 0.6
39 61 M 56 3 2.8 86 0.6 31 18 11 12 1 0.5
40 58 M 89 3.9 3 74 0.5 22 11 6 11.2 0.9 0.9
41 38 M 112 4 3 110 1 45 21 5 11 1.02 0.5
42 56 M 105 4.2 3.2 125 0.9 22 22 6 11.9 1.04 0.4
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43 41 M 116 4.3 2.5 41 0.7 6 5 6 11.1 1.03 0.8
44 32 M 80 3.2 2.8 72 0.3 5 5 12 12.5 1.07 0.8
45 44 M 128 4.5 2 96 0.3 15 11 4 11.1 1 1
46 41 M 122 5 3 69 0.6 32 12 5 12.7 1.1 0.9
47 48 M 107 4 2.1 67 0.6 12 7 10 11.6 1.04 0.8
48 42 M 99 4 2 114 0.3 22 15 2 12.5 1.11 0.8
49 47 M 86 3.8 2.1 200 1.2 8 5 6 11.6 1.04 0.5
50 34 M 123 4.6 3 114 1 29 23 12 11.1 0.9 0.6
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MASTER CHART – CASES
No Age Sex Zinc
µg/dL
Alb
g/dL
Glob
g/dL
ALP
U/L
Bilir
ubin
mg/dL
SGOT
U/L
SGPT
U/L
GGT
U/L
PT
sec
INR Creat
Inine
Mg/dL
MELD Duration
of
alcohol
1 40 M 36 3 2.5 269 6.6 107 52 94 15 1.2 1 16 15
2 32 M 93 3.5 3 235 2.1 109 47 232 16 1.3 0.9 12 6
3 25 M 73 4.3 2.3 180 3.2 112 28 24 16 1.3 0.9 14 5
4 38 M 41 5 3 229 2.05 149 29 25 16 1.3 0.9 12 7
5 57 M 22 2.8 3.2 329 12.05 149 29 323 20 2 1.3 26 30
6 38 M 45 3.5 3.6 232 2.1 107 47 234 18 1.3 1 12 9
7 52 M 26 3.8 3.4 195 6.6 70 20 227 14 1 0.8 14 20
8 37 M 45 3 3 170 2.1 30 16 78 19 1.6 0.7 14 8
9 53 M 28 2.8 3.2 236 6.9 167 40 412 14 1 1.2 15 15
10 47 M 38 3 3 179 4 132 70 221 11.2 1.02 1 12 11
11 45 M 60 3.6 2.8 217 2.97 106 40 95 14 1 0.5 10 6
12 40 M 56 3.9 4.7 140 5.3 78 26 73 17 1.2 1.8 20 7
13 48 M 42 3.8 2.6 210 3.01 187 40 120 12.7 1.1 1 12 16
14 46 M 63 3 2 380 5.6 145 56 71 19 1.6 0.7 18 6
15 40 M 41 3 3.6 488 17.2 161 60 259 21 1.9 6.9 38 20
16 46 M 51 5.3 1.4 239 3.5 29 28 70 14 1 1.3 14 6
17 30 M 45 4.5 2.5 190 8.8 18 28 101 23 2 0.4 22 6
18 62 M 52 4 3.1 375 4.4 45 25 220 17 1.4 1.1 17 20
19 36 M 35 3.2 2.8 220 7.8 26 19 116 29 2.6 0.4 25 7
20 32 M 88 3.1 3.5 232 2.8 50 37 111 14 1 1.3 13 10
21 45 M 42 3 1.7 182 4.16 82 45 361 11 1 0.8 12 20
22 28 M 36 4 3 270 3.7 78 81 20 14 1 1 11 6
23 36 M 44 4.2 3.5 170 3.1 99 76 112 20 1.8 0.7 17 10
24 32 M 65 2 3.9 152 3.9 121 44 77 22 2.02 1.2 21 5
25 37 M 56 3.2 2.8 303 2.2 25 28 101 17 1.4 2.5 22 7
26 40 M 51 4 4 393 3.1 117 198 52 19 1.8 3 28 6
27 55 M 45 2 3.2 252 3.9 121 65 252 22 2.02 1.2 21 10
28 47 M 54 3.6 1.8 124 22.3 113 235 60 15 1.1 2.1 26 6
29 36 M 41 2.4 5.2 308 28 149 189 112 19 1.6 1.2 26 12
30 35 M 48 4.7 3.3 262 2.4 70 160 50 20 1.8 0.7 16 6
31 40 M 41 3 5 323 3.6 121 41 220 22 2 1 19 12
32 42 M 63 4 4.7 390 4.4 70 54 19 25 2.2 1.1 22 5
33 27 M 61 2.3 3.9 425 15.2 99 129 42 20 1.7 1 23 7
34 47 M 59 4 2.8 239 2.3 76 76 50 11 1 0.8 10 8
35 60 M 25 2.3 4.6 375 4 161 82 150 19 1.6 0.6 17 20
36 54 M 32 3.3 2.5 248 12.2 262 38 230 22 2.2 0.3 25 30
37 51 M 44 4.6 3.2 228 0.49 101 21 19 11 1 0.8 6 7
38 35 M 51 2.4 4.2 308 28 171 189 260 19 1.6 0.7 24 17
39 47 M 48 4.3 3.7 530 2.1 77 221 29 21 1.8 0.9 16 6
40 60 M 28 2.3 4.6 375 4 232 53 521 19 1.6 0.6 17 30
41 47 M 51 3.4 2.7 1436 16.3 130 38 140 21 1.8 2.1 31 11
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42 37 M 48 3.7 3.9 277 7.5 117 23 112 22 2 2.16 29 15
43 42 M 52 3.2 2.8 303 2.3 76 25 28 17 1.4 0.8 13 6
44 52 M 37 2.9 2.3 392 22.2 121 198 70 17 1.4 3.2 33 20
45 52 M 31 4.3 4.6 530 2.1 232 221 29 21 1.8 0.9 16 30
46 62 M 53 2.6 1.9 188 0.9 25 49 15 16 1.3 1.2 9 7
47 56 M 50 3.2 2.8 145 1.8 60 36 56 12 1 0.5 17 18
48 35 M 46 2.4 4.2 326 28 165 121 56 16 1.3 1.2 24 20
49 35 M 65 5 3 168 2.3 65 36 40 12 1 0.6 10 6
50 57 M 28 2.3 3.2 234 16 160 45 123 17 1.4 1.2 22 15
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PROFORMA
Case No:
Name of the patient:                                                                Age/Sex
Address:
History Of present illness:
Past History:
Diabetes mellitus: Hypertension: Ischemic Heart disease:
Lung disease Thyroid disease: Dialysis
Liver disease Any other illness
Drug History:
Personal History:
Diet: Smoking Alcohol  :
Type      :
Amount :
Duration :
FAMILY  HISTORY:
PHYSICAL EXAMINATION:
Height weight Pallor Icterus
Clubbing: Cyanosis Lymphadenopathy Thyroid
/ Parotid/ gynaecomastia  /testis/skin             Edema
VITALS
BP                   Pulse Respiratory rate Temp
SYSTEMIC EXAMINATION:
Respiratory System
Cardiovascular System
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Abdominal System
Nervous System
INVESTIGATION:
Plasma Zinc:
Serum Alkaline phosphatase:
OTHERS:
Serum T.Bilirubin
D.Bilirubin
SGOT
SGPT
Total Protein
Albumin
A/G RATIO
Prothrombin time
Serum creatinine
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